Invited Plenary Lecturers

Simeon Arseniyadis (simeon.arseniyadis@icsn.cnrs-gif.fr), Institut de chemie des substances naturelles, Centre national de la reserche scientifique, Gif sur Yvette, France
"The domino approach to molecular complexity: modular construction of synthetically useful heterocyclic frameworks"

Mark C. Bagley (BagleyMC@cardiff.ac.uk), School of Chemistry, Cardiff University, Cardiff, Wales, UK
"Heterocyclic synthesis for chemical intervention in cellular ageing"

Maurice C.R. Franssen (Maurice.Franssen@wur.nl), Laboratory of Organic Chemistry, Wageningen University, The Netherlands
"Chemo-enzymatic synthesis of nitrogen heterocycles"

Michal Hocek (hocek@uochb.cas.cz), Institute of Organic Chemistry and Biochemistry, Academy of Sciences, Prague, Czech Republic
"Cross-couplings and C-H activations of pyrimidines, purines and pyrrolo[2,3-d]pyrimidines. From new nucleoside cytostatics to base-functionalized DNA"

Viktor Krchnak (vkrchnak@nd.edu), Department of Chemistry and Biochemistry, University of Notre Dame, USA
"Efficient and expeditious access to heterocyclic diversity"

Peter Langer (peter.langer@uni-rostock.de), Institut für Chemie, Universität Rostock, Rostock, Germany
"Synthesis of hetero- and carbacycles by cyclizations of free and masked dianions"

Lechoslaw Latos-Grazynski (llg@wchuwr.pl), Department of Chemistry, University of Wroclaw, Poland
"Transformations of porphyrinoids triggered by coordination"

Romano VA Orru (orru@few.vu.nl), Synthetic & Bioorganic Chemistry, Faculty of Sciences,VU University, Amsterdam, The Netherlands
"Multicomponent reaction design in the quest for molecular complexity and diversity"

Kamil Paruch (paruch@chemi.muni.cz), Department of Chemistry Masaryk University, Brno, Czech Republic "Discovery and preclinical profiling of new pyrazolo[1,5-a]pyrimidine-based inhibitors of CDK2 and CHK1 kinases"

John Pavey (john.pavey@astrazeneca.com), AstraZeneca "AZD7009-complicated heterocycle, significant improvements and innovation to deliver a process capable of high volume manufacture"

Jakub Švenda (jakub@svenda.com), Harvard University, USA/Max Planck Institute, Dortmund, Germany "A multiply convergent synthetic route to trioxacarcins"